Novartis

News

All newborns in England will be screened for rare muscle-wasting disease spinal muscular atrophy from 2027, in a landmark move for patients.

News

Fresh from an alliance with Novartis, Chai Discovery has raised $400 million in third-round funding for its AI-based molecular design platform.

Oncology

In a conversation at ASCO 2026, Dr Fred Saad of the University of Montreal shared some insights from a subgroup analysis of Pluvicto

News

Novartis has reached a deal to buy Myricx Bio for up to $1.5bn, giving it control of the London, UK, start-up's ADC platform.

News

Novartis has secured EU approval for Itvisma, a new formulation of its spinal muscular atrophy gene therapy usable in a broader patient population.

News

Novartis' $12bn takeover of Avidity could potentially give it the first therapy for genetic disorder facioscapulohumeral muscular dystrophy.